Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder
- 1 April 1995
- journal article
- clinical trial
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 121 (4) , 239-246
- https://doi.org/10.1007/bf01366969
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cellsZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Characterization of antigen-specific CD4+ effector T cells in vivo: immunization results in a transient population of MEL-14-, CD45RB- helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma.The Journal of Experimental Medicine, 1991
- Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell linesImmunology Letters, 1991
- LOCAL CONTINUOUS HIGH-DOSE INTERLEUKIN-2 - A NEW THERAPEUTIC MODEL FOR THE TREATMENT OF ADVANCED BLADDER-CARCINOMA1989
- Cardiorespiratory effects of immunotherapy with interleukin-2.Journal of Clinical Oncology, 1989
- Conservative Management of Muscle-Infiltrating Bladder Cancer: Prospective ExperienceJournal of Urology, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Clinical effects and toxicity of interleukin-2 in patients with cancerCancer, 1986
- High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated CancerJAMA, 1986
- Human Interleukin 2: Molecular Biology, Physiology and Clinical PossibilitiesImmunobiology, 1986